After Cabometyx’s latest clinical setback Exelixis might have to turn to follow-on projects for future growth.
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.